Table 4

Activity, efficacy and effectiveness of FIr-B/FOx regimen according to KRAS genotype and extension of metastatic disease

All

KRAS wild-type

KRAS mutant


L-L

O/MM

L-L

O/MM

L-L

O/MM


Evaluable patients

25

32

12

18

13

14

Objective response (%; 95% CI)

21 (84; 69 to 99)

24 (80; 64 to 96)

12 (100)

15 (80; 59 to 100)

9 (67; 40 to 94)

9 (80; 54 to 100)

Partial response

18

22

10

13

8

9

Complete response

3 (12)

2 (6)

2 (17)

2 (11)

1 (8)

-

Stable disease

2

3

-

2

2

3

Progressive disease

2

3

-

1

2

2

Liver metastasectomies, N (%)

17 (68)

1 (3)

10 (83)

1 (6)

7 (54)

-

Pathologic complete responses

2 (12)

-

-

-

2

-

Overall activitya, N (%)

20 (80)

3 (9)

12 (100)

3 (17)

8 (62)

-

Median PFS, months

17

12

21

12

11

11

Range

3-69+

1+44

8-69+

4-44

3-60+

1+37

Progression events

20

27

10

15

10

12

P value

0.034

0.044

0.354

Median OS, months

47

21

47

28

39

19

Range

8-69+

1+66+

18+69+

1+66+

8-60+

1+59+

Deaths

12

23

4

13

8

10

P value

0.013

0.017

0.225


aClinical complete response plus metastasectomies.

L-L = liver limited; O/MM = other/multiple metastatic site; OS = overall survival; PFS = progression-free survival.

Bruera et al. BMC Medicine 2012 10:135   doi:10.1186/1741-7015-10-135

Open Data